CALQUENCE in CLL & MCL: Clinical Guide
A practical overview of licensed CALQUENCE use in CLL and MCL, including key efficacy, safety and dosing information relevant to each indication.
Adverse events should be reported
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting contactazmedical.astrazeneca.com or by calling 0800 783 0033.
September 2025 I GB-69434